TEST:

SeekInCare™

"SeekIn Inc...today announced it has received authorization for five U.S. trademarks, further expanding its robust global intellectual property portfolio. The newly registered trademarks—SeekInCare® (blood-based pan-cancer early detection test), OncoSeek® (blood-based, low-cost multi-cancer early detection test), SeekInClarity® (blood-based pan-cancer treatment response monitoring test), LeukoPrint® (molecular karyotyping test for hematologic malignancies), and PanCanSeek® (precision diagnosis and therapeutic guidance for hematologic malignancies)—mark a significant milestone following successful trademark registrations in China and the European Union."

"SeekIn Inc...announced that it has obtained authorization to use five trademarks within the United States, including SeekInCare® (blood-based pan-cancer early detection test), OncoSeek® (blood-based low-cost multi-cancer early detection test), SeekInClarity® (blood-based pan-cancer treatment response monitoring test), LeukoPrint® (hematologic malignancies molecular karyotyping test), and PanCanSeek® (hematologic malignancies precision diagnosis and therapeutics guidance test). These acquisitions strengthen SeekIn Inc.'s intellectual property portfolio and open new avenues for the company to expand its reach and enhance its services within the United States."

"SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, unveiled cost-effective Two-Step multi-cancer screening strategy and breakthrough lung cancer early detection test at NKI Early Cancer Detection Conference 2025, ushering in a new era of cancer screening."

The performances of SeekInCare in both retrospective and prospective studies demonstrate that SeekInCare is a blood-based MCED test, showing comparable performance to the other tests currently in development. These findings support its potential clinical utility as a cancer screening test in high-risk populations.

The cost of per cancer case detected was $117,133 for SeekInCare and $172,828 for Galleri, which were 3.5-fold and 5.2-fold higher, respectively, than the two-step MCED ($33,534). The two-step approach not only significantly reduces false positives, but also cuts the screening cost down substantially, making it a cost-effective strategy for population-wide cancer screening.

"SeekIn Inc...announced today its innovative two-step multi-cancer screening strategy at the Early Detection of Cancer Conference in San Francisco...SeekIn also debuted the findings from its lung cancer early detection test study, marking a significant advancement in the field of cancer screening...In a study with 1,197 participants (617 with cancer and 580 without), the two-step MCED approach achieved a remarkable 12.9-fold reduction in the false positive rate, from 9.0% to 0.7%. When applied to a hypothetical screening of five million adults, the strategy reduced total cost by 6.6-fold ($713.6 million compared to $4,745 million) and cost per cancer patient identified by 5.2-fold ($33,534 compared to $172,828)...In a study of 1,814 participants...from three cohorts, LungCanSeek showed 83.5% sensitivity and 90.3% specificity by combining artificial intelligence (AI) algorithms with four protein tumor markers (PTMs)."

"SeekIn Inc...announced today that it has obtained authorization to use eight trademarks within the European Union, including SeekInCare (the first-in-class blood-based pan-cancer early detection test), SeekInCure (the first-in-class blood-based pan-cancer recurrence monitoring test), SeekInClarity (pan-cancer treatment response monitoring), OncoSeek (low-cost early cancer detection test), LungCanSeek (lung cancer early detection test), LeukoPrint (the first-in-class leukemia sWGS CNA test), PanCanSeek (pan-cancer therapy guidance test)..."

The performances of SeekInCare in both retrospective and prospective studies demonstrate that SeekInCare is an effective blood-based MCED test with similar performance as Grail's Galleri test, which paves the way for clinical utility as a cancer screening test in average-risk populations.

In summary, a blood-based assay can be an alternative to detect lymphoma with adequate performance. This approach becomes particularly valuable in cases where obtaining tissue biopsy is difficult to obtain or inconclusive.

"SeekIn Inc...announced a strategic collaboration with Oncolnv, a fully-owned affiliate of Inspire2Live, to expand the global accessibility of their multiple cancer detection tests and bridge disparities in cancer care. Starting this December, SeekIn's comprehensive range of cancer detection tests, namely OncoSeek, SeekInCare, SeekInCure and SeekInClarity will be distributed by Oncolnv in the following twelve countries: Belgium, Bulgaria, Costa Rica, Egypt, Ghana, Kenya, the Netherlands, Nigeria, Qatar, Singapore, Tanzania and UAE."

"SeekIn Inc...announced the validation studies consisting of one retrospective cohort and one prospective cohort that evaluate SeekInCare's ability to detect cancer patients and predict the tissue of origin with one tube of blood. The results demonstrate the performance of SeekInCare with the consistent results among the two cohorts in ~2,400 cancer patients and non-cancer individuals. SeekInCare achieved overall 65.5% sensitivity at 97.9% specificity in the retrospective studies and 60.0% sensitivity at 96.1% specificity in the prospective cohort study, respectively, which is best-in-class in blood-based multi-cancer early detection (MCED). The findings were presented at the 20th ICGC Workshop and 7th ARGO Meeting in New York."

Our study found CA125 and EBV profiles as potential biomarkers for lymphoma screening, and confirmed that the non-invasive SeekInCare assay could be used to detect lymphoma with accuracy. Positive predictive value and negative predictive value were more than 90.0%, especially for which biopsies that were inconclusive.